Page last updated: 2024-11-03

probenecid and Leukemia, Myeloid, Acute

probenecid has been researched along with Leukemia, Myeloid, Acute in 2 studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Copsel, S1
Garcia, C1
Diez, F1
Vermeulem, M1
Baldi, A1
Bianciotti, LG1
Russel, FG1
Shayo, C1
Davio, C1
Kim, HS1
Min, YD1
Choi, CH1

Other Studies

2 other studies available for probenecid and Leukemia, Myeloid, Acute

ArticleYear
Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.
    The Journal of biological chemistry, 2011, Mar-04, Volume: 286, Issue:9

    Topics: Cell Differentiation; Cell Division; Cyclic AMP; Drug Design; HL-60 Cells; Humans; Leukemia, Myeloid

2011
Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
    Biochemical and biophysical research communications, 2001, Apr-27, Volume: 283, Issue:1

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette

2001